View in EDS

Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners.

Saved in:
Bibliographic Details
Title: Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners.
Authors: Doshi AS; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Cantin S; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Hernandez M; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Srinivasan S; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Tentarelli S; Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Griffin M; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Wang Y; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Pop-Damkov P; Drug Metabolism and Pharmacokinetics, Oncology R&D, Waltham, Massachusetts., Prickett LB; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Kankkonen C; Discovery Sciences, R&D, AstraZeneca, Mölndal, Sweden., Shen M; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Martin MS; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Wu S; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Castaldi MP; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts., Ghadially H; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Varnes J; Global Portfolio and Project Management, Waltham, Massachusetts., Gales S; Toxicology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Toxicology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Henry D; Toxicology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Toxicology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Hoover C; Safety Pathology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Mele DA; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Simpson I; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Gangl ET; Drug Metabolism and Pharmacokinetics, Oncology R&D, Waltham, Massachusetts., Mlynarski SN; Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Finlay MRV; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Drew L; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Fawell SE; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Shao W; Projects, Oncology R&D, AstraZeneca, Boston, Massachusetts., Schuller AG; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2023 May 04; Vol. 22 (5), pp. 630-645.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36912782
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Doshi+AS%22">Doshi AS</searchLink>; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Cantin+S%22">Cantin S</searchLink>; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Hernandez+M%22">Hernandez M</searchLink>; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Srinivasan+S%22">Srinivasan S</searchLink>; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Tentarelli+S%22">Tentarelli S</searchLink>; Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Griffin+M%22">Griffin M</searchLink>; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Pop-Damkov+P%22">Pop-Damkov P</searchLink>; Drug Metabolism and Pharmacokinetics, Oncology R&D, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Prickett+LB%22">Prickett LB</searchLink>; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Kankkonen+C%22">Kankkonen C</searchLink>; Discovery Sciences, R&D, AstraZeneca, Mölndal, Sweden.<br /><searchLink fieldCode="AU" term="%22Shen+M%22">Shen M</searchLink>; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Martin+MS%22">Martin MS</searchLink>; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Wu+S%22">Wu S</searchLink>; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland.<br /><searchLink fieldCode="AU" term="%22Castaldi+MP%22">Castaldi MP</searchLink>; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Ghadially+H%22">Ghadially H</searchLink>; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Varnes+J%22">Varnes J</searchLink>; Global Portfolio and Project Management, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Gales+S%22">Gales S</searchLink>; Toxicology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Toxicology, Oncology R&D, AstraZeneca, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Henry+D%22">Henry D</searchLink>; Toxicology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Toxicology, Oncology R&D, AstraZeneca, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Hoover+C%22">Hoover C</searchLink>; Safety Pathology, Oncology R&D, AstraZeneca, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Mele+DA%22">Mele DA</searchLink>; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Simpson+I%22">Simpson I</searchLink>; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Gangl+ET%22">Gangl ET</searchLink>; Drug Metabolism and Pharmacokinetics, Oncology R&D, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Mlynarski+SN%22">Mlynarski SN</searchLink>; Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Finlay+MRV%22">Finlay MRV</searchLink>; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Drew+L%22">Drew L</searchLink>; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Fawell+SE%22">Fawell SE</searchLink>; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Shao+W%22">Shao W</searchLink>; Projects, Oncology R&D, AstraZeneca, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Schuller+AG%22">Schuller AG</searchLink>; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2023 May 04; Vol. 22 (5), pp. 630-645.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36912782
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-22-0431
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 630
    Titles:
      – TitleFull: Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Doshi AS
      – PersonEntity:
          Name:
            NameFull: Cantin S
      – PersonEntity:
          Name:
            NameFull: Hernandez M
      – PersonEntity:
          Name:
            NameFull: Srinivasan S
      – PersonEntity:
          Name:
            NameFull: Tentarelli S
      – PersonEntity:
          Name:
            NameFull: Griffin M
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: Pop-Damkov P
      – PersonEntity:
          Name:
            NameFull: Prickett LB
      – PersonEntity:
          Name:
            NameFull: Kankkonen C
      – PersonEntity:
          Name:
            NameFull: Shen M
      – PersonEntity:
          Name:
            NameFull: Martin MS
      – PersonEntity:
          Name:
            NameFull: Wu S
      – PersonEntity:
          Name:
            NameFull: Castaldi MP
      – PersonEntity:
          Name:
            NameFull: Ghadially H
      – PersonEntity:
          Name:
            NameFull: Varnes J
      – PersonEntity:
          Name:
            NameFull: Gales S
      – PersonEntity:
          Name:
            NameFull: Henry D
      – PersonEntity:
          Name:
            NameFull: Hoover C
      – PersonEntity:
          Name:
            NameFull: Mele DA
      – PersonEntity:
          Name:
            NameFull: Simpson I
      – PersonEntity:
          Name:
            NameFull: Gangl ET
      – PersonEntity:
          Name:
            NameFull: Mlynarski SN
      – PersonEntity:
          Name:
            NameFull: Finlay MRV
      – PersonEntity:
          Name:
            NameFull: Drew L
      – PersonEntity:
          Name:
            NameFull: Fawell SE
      – PersonEntity:
          Name:
            NameFull: Shao W
      – PersonEntity:
          Name:
            NameFull: Schuller AG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 05
              Text: 2023 May 04
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 22
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1